|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Blackburn BE, Ganz PA, Rowe K, Snyder J,
Wan Y, Deshmukh V, Newman M, Fraser A, Smith K, Herget K, et al:
Aging-related disease risks among young thyroid cancer survivors.
Cancer Epidemiol Biomarkers Prev. 26:1695–1704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Janz TA, Neskey DM, Nguyen SA and Lentsch
EJ: Is the incidence of anaplastic thyroid cancer increasing: A
population based epidemiology study. World J Otorhinolaryngol Head
Neck Surg. 5:34–40. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Labuschagne CF, Zani F and Vousden KH:
Control of metabolism by p53-cancer and beyond. Biochim Biophys
Acta Rev Cancer. 1870:32–42. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Muller PA and Vousden KH: p53 mutations in
cancer. Nat Cell Biol. 15:2–8. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manzella L, Stella S, Pennisi MS, Tirro E,
Massimino M, Romano C, Puma A, Tavarelli M and Vigneri P: New
insights in thyroid cancer and p53 family proteins. Int J Mol Sci.
18:E13252017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Wang Z, Chen Y, Petersen RB, Zheng L
and Huang K: Salvation of the fallen angel: Reactivating mutant
p53. Br J Pharmacol. 176:817–831. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu L, Li D, Chen Z, Yang J, Ma Y, Cai H,
Shan C, Lv Z and Zhang X: Wild-type p53 induces sodium/iodide
symporter expression allowing radioiodide therapy in anaplastic
thyroid cancer. Cell Physiol Biochem. 43:905–914. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Date E, Okamoto K, Fumita S and Kaneda H:
Gastrointestinal perforation related to lenvatinib, an
anti-angiogenic inhibitor that targets multiple receptor tyrosine
kinases, in a patient with metastatic thyroid cancer. Invest New
Drugs. 36:350–353. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saito Y, Sugino K, Takami H, Matsuzu K,
Uruno T, Ohkuwa K, Kitagawa W, Nagahama M, Kawakubo H, Ito K and
Kitagawa Y: Clinical status and treatment of liver metastasis of
differentiated thyroid cancer using tyrosine kinase inhibitors.
World J Surg. 42:3632–3637. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Corrado A, Ferrari SM, Politti U, Mazzi V,
Miccoli M, Materazzi G, Antonelli A, Ulisse S, Fallahi P and
Miccoli P: Aggressive thyroid cancer: Targeted therapy with
sorafenib. Minerva Endocrinol. 42:64–76. 2017.PubMed/NCBI
|
|
13
|
Ramakrishnan V, Timm M, Haug JL, Kimlinger
TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA and Kumar S:
Sorafenib, a dual Raf kinase/vascular endothelial growth factor
receptor inhibitor has significant anti-myeloma activity and
synergizes with common anti-myeloma drugs. Oncogene. 29:1190–1202.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ito Y, Onoda N, Ito KI, Sugitani I,
Takahashi S, Yamaguchi I, Kabu K and Tsukada K: Sorafenib in
Japanese patients with locally advanced or metastatic medullary
thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid.
27:1142–1148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen G, Nicula D, Renko K and Derwahl M:
Synergistic anti-proliferative effect of metformin and sorafenib on
growth of anaplastic thyroid cancer cells and their stem cells.
Oncol Rep. 33:1994–2000. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Orlandi F, Caraci P, Berruti A, Puligheddu
B, Pivano G, Dogliotti L and Angeli A: Chemotherapy with
dacarbazine and 5-fluorouracil in advanced medullary thyroid
cancer. Ann Oncol. 5:763–765. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Binayke A, Mishra S, Suman P, Das S and
Chander H: Awakening the ‘guardian of genome’: Reactivation of
mutant p53. Cancer Chemother Pharmacol. 83:1–15. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mularski J, Malarz K, Pacholczyk M and
Musiol R: The p53 stabilizing agent CP-31398 and multi-kinase
inhibitors. Designing, synthesizing and screening of
styrylquinazoline series. Eur J Med Chem. 163:610–625. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beberok A, Rzepka Z, Respondek M, Rok J,
Stradowski M and Wrześniok D: Moxifloxacin as an inducer of
apoptosis in melanoma cells: A study at the cellular and molecular
level. Toxicol In Vitro. 55:75–92. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang LC, Tam KW, Liu WN, Lin CY, Hsu KW,
Hsieh WS, Chi WM, Lee AW, Yang JM, Lin CL and Lee CH: CRISPR/Cas9
genome editing of epidermal growth factor receptor sufficiently
abolished oncogenicity in anaplastic thyroid cancer. Dis Markers.
2018:38357832018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshimoto K, Iwahana H, Fukuda A, Sano T,
Saito S and Itakura M: Role of p53 mutations in endocrine
tumorigenesis: Mutation detection by polymerase chain
reaction-single strand conformation polymorphism. Cancer Res.
52:5061–5064. 1992.PubMed/NCBI
|
|
22
|
Liu L, Yu TT, Ren CC, Yang L, Cui SH and
Zhang XA: CP-31398 inhibits the progression of cervical cancer
through reversing the epithelial mesenchymal transition via the
downregulation of PAX2s. J Cell Physiol. 234:2929–2942. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhong B, Shingyoji M, Hanazono M, Nguyen
TTT, Morinaga T, Tada Y, Hiroshima K, Shimada H and Tagawa M: A
p53-stabilizing agent, CP-31398, induces p21 expression with
increased G2/M phase through the YY1 transcription factor in
esophageal carcinoma defective of the p53 pathway. Am J Cancer Res.
9:79–93. 2019.PubMed/NCBI
|
|
24
|
Krajewska J, Handkiewicz-Junak D and
Jarzab B: Sorafenib for the treatment of thyroid cancer: An updated
review. Expert Opin Pharmacother. 16:573–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Zhang Y, Zhang Q, Zhu G, Zhang Z,
Duan C, Lu T and Tang W: Discovery of potent Pan-Raf inhibitors
with increased solubility to overcome drug resistance. Eur J Med
Chem. 163:243–255. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Salehian B, Liem SY, Mojazi Amiri H and
Maghami E: Clinical trials in management of anaplastic thyroid
carcinoma; progressions and set backs: A systematic review. Int J
Endocrinol Metab. 17:e677592019.PubMed/NCBI
|
|
27
|
Liu TR, Xiao ZW, Xu HN, Long Z, Wei FQ,
Zhuang SM, Sun XM, Xie LE, Mu JS, Yang AK, et al: Treatment and
prognosis of anaplastic thyroid carcinoma: A clinical study of 50
cases. PLoS One. 11:e01648402016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Danilovic DLS, Castro G Jr, Roitberg FSR,
Vanderlei FAB, Bonani FA, Freitas RMC, Coura-Filho GB, Camargo RY,
Kulcsar MA, Marui S and Hoff AO: Potential role of sorafenib as
neoadjuvant therapy in unresectable papillary thyroid cancer. Arch
Endocrinol Metab. 62:370–375. 2018.PubMed/NCBI
|
|
29
|
Arihara Y, Takada K, Kamihara Y, Hayasaka
N, Nakamura H, Murase K, Ikeda H, Iyama S, Sato T, Miyanishi K, et
al: Small molecule CP-31398 induces reactive oxygen
species-dependent apoptosis in human multiple myeloma. Oncotarget.
8:65889–65899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He XX, Zhang YN, Yan JW, Yan JJ, Wu Q and
Song YH: CP-31398 inhibits the growth of p53-mutated liver cancer
cells in vitro and in vivo. Tumour Biol. 37:807–815. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grassi ES, Vezzoli V, Negri I, Labadi A,
Fugazzola L, Vitale G and Persani L: SP600125 has a remarkable
anticancer potential against undifferentiated thyroid cancer
through selective action on ROCK and p53 pathways. Oncotarget.
6:36383–36399. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu J, Timares L, Heilpern C, Weng Z, Li C,
Xu H, Pressey JG, Elmets CA, Kopelovich L and Athar M: Targeting
wild-type and mutant p53 with small molecule CP-31398 blocks the
growth of rhabdomyosarcoma by inducing reactive oxygen
species-dependent apoptosis. Cancer Res. 70:6566–6576. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karimian A, Ahmadi Y and Yousefi B:
Multiple functions of p21 in cell cycle, apoptosis and
transcriptional regulation after DNA damage. DNA Repair (Amst).
42:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shibue T, Takeda K, Oda E, Tanaka H,
Murasawa H, Takaoka A, Morishita Y, Akira S, Taniguchi T and Tanaka
N: Integral role of Noxa in p53-mediated apoptotic response. Genes
Dev. 17:2233–2238. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tran Cao HS, Kaushal S, Snyder CS, Ongkeko
WM, Hoffman RM and Bouvet M: Real-time imaging of tumor progression
in a fluorescent orthotopic mouse model of thyroid cancer.
Anticancer Res. 30:4415–4422. 2010.PubMed/NCBI
|
|
36
|
Kim S, Yazici YD, Calzada G, Wang ZY,
Younes MN, Jasser SA, El-Naggar AK and Myers JN: Sorafenib inhibits
the angiogenesis and growth of orthotopic anaplastic thyroid
carcinoma xenografts in nude mice. Mol Cancer Ther. 6:1785–1792.
2007. View Article : Google Scholar : PubMed/NCBI
|
